Acute somatomedin response to growth hormone: Radioreceptor assay versus radioimmunoassay

S. F. Kemp, Ronald (Ron) Rosenfeld, F. Liu, S. Gaspich, R. L. Hintz

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The acute somatomedin (SM) response to GH therapy has been examined in 21 GH-deficient children using a placental membrane radioreceptor assay (RRA) which measures a variety of SMs and a RIA specific for SM-C and insulin-like growth factor I (IGF-I). Plasma for determination of SM peptide content was obtained before initiation of therapy and 13 h after each of four daily injections of GH (0.1 U/kg). An additional SM determination was performed after 6 weeks of GH therapy (0.1 U/kg, three times per week) in seven of the subjects. RRA and RIA SM determinations were performed on the same acid-chromatographed sample and were compared to an acid-chromatographed pooled plasma standard. The 4 days of GH therapy resulted in an increase in SM levels from 0.39 ± 0.24 to 1.18 ± 0.62 (±SD) U/ml, determined by RIA. A single injection of GH resulted in a significant rise in plasma SM levels, measured by either RRA or RIA (P <0.001). Subjects who responded poorly to two injections of GH also had low SM levels after 4 days and even after 6 weeks of GH therapy. The RRA resulted in consistently higher values than the RIA. This difference was even greater when results were compared to a pure IGF-I/SM-C standard. The SM peptide contents determined by RRA and RIA were strongly correlated, not only for the group, but also among the determinations for each individual subject. However, the consistently higher values observed when the SM peptide content was measured by RRA compared to that measured by RIA and the variability in the RRA to RIA ratio among individual subjects suggest that the IGF-I/SM-C RIA measures only one of a number of GH-dependent SM peptides.

Original languageEnglish (US)
Pages (from-to)616-621
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume52
Issue number4
StatePublished - 1981
Externally publishedYes

Fingerprint

Radioligand Assay
Somatomedins
Growth Hormone
Radioimmunoassay
Assays
Insulin-Like Growth Factor I
Peptides
Plasmas
Injections
Therapeutics
Acids
Membranes

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Kemp, S. F., Rosenfeld, R. R., Liu, F., Gaspich, S., & Hintz, R. L. (1981). Acute somatomedin response to growth hormone: Radioreceptor assay versus radioimmunoassay. Journal of Clinical Endocrinology and Metabolism, 52(4), 616-621.

Acute somatomedin response to growth hormone : Radioreceptor assay versus radioimmunoassay. / Kemp, S. F.; Rosenfeld, Ronald (Ron); Liu, F.; Gaspich, S.; Hintz, R. L.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 52, No. 4, 1981, p. 616-621.

Research output: Contribution to journalArticle

Kemp, SF, Rosenfeld, RR, Liu, F, Gaspich, S & Hintz, RL 1981, 'Acute somatomedin response to growth hormone: Radioreceptor assay versus radioimmunoassay', Journal of Clinical Endocrinology and Metabolism, vol. 52, no. 4, pp. 616-621.
Kemp, S. F. ; Rosenfeld, Ronald (Ron) ; Liu, F. ; Gaspich, S. ; Hintz, R. L. / Acute somatomedin response to growth hormone : Radioreceptor assay versus radioimmunoassay. In: Journal of Clinical Endocrinology and Metabolism. 1981 ; Vol. 52, No. 4. pp. 616-621.
@article{12b8a0f237dd4d8d968f1a6a95460967,
title = "Acute somatomedin response to growth hormone: Radioreceptor assay versus radioimmunoassay",
abstract = "The acute somatomedin (SM) response to GH therapy has been examined in 21 GH-deficient children using a placental membrane radioreceptor assay (RRA) which measures a variety of SMs and a RIA specific for SM-C and insulin-like growth factor I (IGF-I). Plasma for determination of SM peptide content was obtained before initiation of therapy and 13 h after each of four daily injections of GH (0.1 U/kg). An additional SM determination was performed after 6 weeks of GH therapy (0.1 U/kg, three times per week) in seven of the subjects. RRA and RIA SM determinations were performed on the same acid-chromatographed sample and were compared to an acid-chromatographed pooled plasma standard. The 4 days of GH therapy resulted in an increase in SM levels from 0.39 ± 0.24 to 1.18 ± 0.62 (±SD) U/ml, determined by RIA. A single injection of GH resulted in a significant rise in plasma SM levels, measured by either RRA or RIA (P <0.001). Subjects who responded poorly to two injections of GH also had low SM levels after 4 days and even after 6 weeks of GH therapy. The RRA resulted in consistently higher values than the RIA. This difference was even greater when results were compared to a pure IGF-I/SM-C standard. The SM peptide contents determined by RRA and RIA were strongly correlated, not only for the group, but also among the determinations for each individual subject. However, the consistently higher values observed when the SM peptide content was measured by RRA compared to that measured by RIA and the variability in the RRA to RIA ratio among individual subjects suggest that the IGF-I/SM-C RIA measures only one of a number of GH-dependent SM peptides.",
author = "Kemp, {S. F.} and Rosenfeld, {Ronald (Ron)} and F. Liu and S. Gaspich and Hintz, {R. L.}",
year = "1981",
language = "English (US)",
volume = "52",
pages = "616--621",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Acute somatomedin response to growth hormone

T2 - Radioreceptor assay versus radioimmunoassay

AU - Kemp, S. F.

AU - Rosenfeld, Ronald (Ron)

AU - Liu, F.

AU - Gaspich, S.

AU - Hintz, R. L.

PY - 1981

Y1 - 1981

N2 - The acute somatomedin (SM) response to GH therapy has been examined in 21 GH-deficient children using a placental membrane radioreceptor assay (RRA) which measures a variety of SMs and a RIA specific for SM-C and insulin-like growth factor I (IGF-I). Plasma for determination of SM peptide content was obtained before initiation of therapy and 13 h after each of four daily injections of GH (0.1 U/kg). An additional SM determination was performed after 6 weeks of GH therapy (0.1 U/kg, three times per week) in seven of the subjects. RRA and RIA SM determinations were performed on the same acid-chromatographed sample and were compared to an acid-chromatographed pooled plasma standard. The 4 days of GH therapy resulted in an increase in SM levels from 0.39 ± 0.24 to 1.18 ± 0.62 (±SD) U/ml, determined by RIA. A single injection of GH resulted in a significant rise in plasma SM levels, measured by either RRA or RIA (P <0.001). Subjects who responded poorly to two injections of GH also had low SM levels after 4 days and even after 6 weeks of GH therapy. The RRA resulted in consistently higher values than the RIA. This difference was even greater when results were compared to a pure IGF-I/SM-C standard. The SM peptide contents determined by RRA and RIA were strongly correlated, not only for the group, but also among the determinations for each individual subject. However, the consistently higher values observed when the SM peptide content was measured by RRA compared to that measured by RIA and the variability in the RRA to RIA ratio among individual subjects suggest that the IGF-I/SM-C RIA measures only one of a number of GH-dependent SM peptides.

AB - The acute somatomedin (SM) response to GH therapy has been examined in 21 GH-deficient children using a placental membrane radioreceptor assay (RRA) which measures a variety of SMs and a RIA specific for SM-C and insulin-like growth factor I (IGF-I). Plasma for determination of SM peptide content was obtained before initiation of therapy and 13 h after each of four daily injections of GH (0.1 U/kg). An additional SM determination was performed after 6 weeks of GH therapy (0.1 U/kg, three times per week) in seven of the subjects. RRA and RIA SM determinations were performed on the same acid-chromatographed sample and were compared to an acid-chromatographed pooled plasma standard. The 4 days of GH therapy resulted in an increase in SM levels from 0.39 ± 0.24 to 1.18 ± 0.62 (±SD) U/ml, determined by RIA. A single injection of GH resulted in a significant rise in plasma SM levels, measured by either RRA or RIA (P <0.001). Subjects who responded poorly to two injections of GH also had low SM levels after 4 days and even after 6 weeks of GH therapy. The RRA resulted in consistently higher values than the RIA. This difference was even greater when results were compared to a pure IGF-I/SM-C standard. The SM peptide contents determined by RRA and RIA were strongly correlated, not only for the group, but also among the determinations for each individual subject. However, the consistently higher values observed when the SM peptide content was measured by RRA compared to that measured by RIA and the variability in the RRA to RIA ratio among individual subjects suggest that the IGF-I/SM-C RIA measures only one of a number of GH-dependent SM peptides.

UR - http://www.scopus.com/inward/record.url?scp=0019735812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019735812&partnerID=8YFLogxK

M3 - Article

C2 - 7204536

AN - SCOPUS:0019735812

VL - 52

SP - 616

EP - 621

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -